Sanara Medtech Net Worth
Sanara Medtech Net Worth Breakdown | SMTI |
Sanara Medtech Net Worth Analysis
Sanara Medtech's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Sanara Medtech's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Sanara Medtech's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Sanara Medtech's net worth analysis. One common approach is to calculate Sanara Medtech's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Sanara Medtech's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Sanara Medtech's net worth. This approach calculates the present value of Sanara Medtech's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Sanara Medtech's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Sanara Medtech's net worth. This involves comparing Sanara Medtech's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Sanara Medtech's net worth relative to its peers.
Enterprise Value |
|
To determine if Sanara Medtech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sanara Medtech's net worth research are outlined below:
| The company reported the previous year's revenue of 64.99 M. Net Loss for the year was (4.3 M) with profit before overhead, payroll, taxes, and interest of 70.38 M. | |
| Sanara Medtech currently holds about 12.68 M in cash with (3.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.53. | |
| Sanara Medtech has a frail financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Michael McNeil of 6547 shares of Sanara Medtech subject to Rule 16b-3 |
Sanara Medtech Quarterly Good Will |
|
Sanara Medtech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sanara Medtech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sanara Medtech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Sanara Medtech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sanara Medtech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sanara Medtech backward and forwards among themselves. Sanara Medtech's institutional investor refers to the entity that pools money to purchase Sanara Medtech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-12-31 | 15.9 K | Squarepoint Ops Llc | 2024-12-31 | 14.8 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 13.8 K | Jpmorgan Chase & Co | 2024-12-31 | 13.6 K | Bank Of New York Mellon Corp | 2024-12-31 | 13.1 K | Goldman Sachs Group Inc | 2024-12-31 | 12.3 K | Charles Schwab Investment Management Inc | 2024-12-31 | 11.4 K | Salem Investment Counselors Inc | 2024-12-31 | 11.2 K | Stephens Inc | 2024-12-31 | 10.8 K | Blackrock Inc | 2024-12-31 | 215 K | Vanguard Group Inc | 2024-12-31 | 200.8 K |
Follow Sanara Medtech's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 287.58 M.Market Cap |
|
Project Sanara Medtech's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.06) | (0.07) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.09) | (0.09) |
When accessing Sanara Medtech's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Sanara Medtech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sanara Medtech's profitability and make more informed investment decisions.
Evaluate Sanara Medtech's management efficiency
Sanara Medtech has return on total asset (ROA) of (0.0508) % which means that it has lost $0.0508 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2028) %, meaning that it created substantial loss on money invested by shareholders. Sanara Medtech's management efficiency ratios could be used to measure how well Sanara Medtech manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.16. The current Return On Capital Employed is estimated to decrease to -0.07. As of now, Sanara Medtech's Total Current Assets are increasing as compared to previous years. The Sanara Medtech's current Intangible Assets is estimated to increase to about 54.2 M, while Non Currrent Assets Other are forecasted to increase to (16.3 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.85 | 5.09 | |
| Tangible Book Value Per Share | (0.43) | (0.45) | |
| Enterprise Value Over EBITDA | -1.1 K | -1 K | |
| Price Book Value Ratio | 6.83 | 7.17 | |
| Enterprise Value Multiple | -1.1 K | -1 K | |
| Price Fair Value | 6.83 | 7.17 | |
| Enterprise Value | 312.2 M | 176.8 M |
Understanding the operational decisions made by Sanara Medtech management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 3.8209 | Revenue | Quarterly Revenue Growth 0.352 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sanara Medtech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sanara Medtech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sanara Medtech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sanara Medtech Corporate Filings
F4 | 27th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 22nd of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F3 | 15th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Sanara Medtech Earnings per Share Projection vs Actual
Sanara Medtech Corporate Management
| Bill Fitzgerald | Compliance Officer | Profile | |
| Jacob Waldrop | Chief Officer | Profile | |
| Callon Nichols | Director Relations | Profile | |
| Elizabeth Taylor | Chief Officer | Profile | |
| Jane Fore | Chief Officer | Profile | |
| Tricia Matteson | Director Marketing | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanara Medtech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanara Medtech. If investors know Sanara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanara Medtech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share | Quarterly Revenue Growth 0.352 | Return On Assets | Return On Equity |
The market value of Sanara Medtech is measured differently than its book value, which is the value of Sanara that is recorded on the company's balance sheet. Investors also form their own opinion of Sanara Medtech's value that differs from its market value or its book value, called intrinsic value, which is Sanara Medtech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanara Medtech's market value can be influenced by many factors that don't directly affect Sanara Medtech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanara Medtech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanara Medtech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanara Medtech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.